# May Measurement Month 2019: an analysis of blood pressure screening results from Lebanon 

Robert N. Najem ${ }^{1,2 *}$, Ahmad Halawi ${ }^{3}$, Bassem Tanios ${ }^{4}$, Rasha Ambriss ${ }^{5}$, Rana El Bikai ${ }^{6}$, Giles Partington ${ }^{7}$, Thomas Beaney ${ }^{7,8}$, Neil R. Poulter ${ }^{7}$, and Ali K. Abu Alfa ${ }^{4}$<br>${ }^{1}$ Division of Nephrology, Department of Internal Medicine, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon<br>${ }^{2}$ Lebanese Hospital Geitawi University Medical Center, Beirut, Lebanon<br>${ }^{3}$ Department of Internal Medicine, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon<br>${ }^{4}$ Division of Nephrology and Hypertension, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon<br>${ }^{5}$ Ministry of Public Health, Beirut, Lebanon<br>${ }^{6}$ Public Health Department, Faculty of Health Sciences, University of Balamand, Beirut, Lebanon<br>${ }^{7}$ Imperial Clinical Trials Unit, Imperial College London, Stadium House, London, UK;and<br>${ }^{8}$ Department of Primary Care and Public Health, Imperial College London, London, UK

## KEYWORDS

Hypertension;
Blood pressure;
Screening;
Treatment;
Lebanon

Hypertension is an important public health concern of high prevalence among adults. It is associated with an increased mortality rate. The prevalence of hypertension in Lebanon has increased during the last decades, affecting around one-third of the Lebanese population. Since diagnosis and treatment of hypertension is associated with a better prognosis, annual screening and raising awareness about this 'silent killer' disease is of extreme value. We conducted a cross-sectional survey in various Lebanese cities in 2019. We recruited adults ( $\geq 18$ years old) from different sites, through an opportunistic sampling method. For each participant, three blood pressure (BP) readings were recorded and the average of the last two was analysed. In addition, data on lifestyle factors and comorbidities were collected. Participants were considered hypertensive if they had at least one of the following: systolic or diastolic $\mathrm{BP} \geq 140$ and/or $\geq 90 \mathrm{mmHg}$, respectively, or taking antihypertensive medication. Blood pressure was measured in 7019 participants. The mean age was 46.0 (SD 16.6) years. In total, 2572 participants ( $36.6 \%$ ) had hypertension among whom only $64.1 \%$ were aware of their disease and $62.3 \%$ were on treatment. Blood pressure was controlled in $62.6 \%$ of participants taking antihypertensive medications. This study is the largest on hypertension prevalence in Lebanon. The results demonstrated that around one-third of the hypertensive population were not aware of their disease, and that a high percentage was not being treated. These results suggest the need for rapid interventions aimed at raising awareness regarding hypertension in the Lebanese population.

[^0]
## Introduction

The burden of hypertension is increasing tremendously, affecting 1.4 billion people all over the globe. ${ }^{1}$ Uncontrolled
hypertension is directly linked to an increase in all-cause and cardiovascular disease (CVD) mortality in adults. ${ }^{2}$

Prevalence of hypertension varies worldwide and was found to be $29.5 \%$ in the Arab world. ${ }^{3}$ Lebanon, a country in the Arab world and the Middle East, has an estimated population of $\sim 6.8$ million. The prevalence of hypertension in Lebanon increased from $23.1 \%$ as reported in 2005 to $36.4 \%$ in 2018. ${ }^{4,5}$ Moreover, CVD such as stroke and myocardial infarction was found in $2.4 \%$ and $4.3 \%$, respectively, of hypertensive patients. ${ }^{4}$

Since only around half of patients with hypertension in Lebanon are aware of their disease as reported previously, screening for hypertension and increasing awareness is of tremendous importance for the population in Lebanon. ${ }^{6}$ After successful participation in the May Measurement Month (MMM) 2018 campaign, Lebanon participated again in the MMM 2019 campaign, which is an initiative led by the International Society of Hypertension and endorsed by the World Hypertension League. In this article, we will report the main results of MMM 2019 campaign in Lebanon.

## Methods

May Measurement Month 2019 was led by the Lebanese Society of Nephrology and Hypertension in partnership with the Lebanese Society of Cardiology and the Lebanese Ministry of Public Health. Clearance was obtained from the Ministry of Public Health, with ethical/administrative approval granted by individual institutions as applicable, coupled with individual verbal consent to share anonymized data. Twenty Lebanese cities were covered by the campaign. Blood pressure (BP) screening took place at outdoors public areas. Members of the teams were mainly from the medical field (nurses, medical students, doctors, pharmacists) with experience of measuring $B P$.

May Measurement Month is a cross-sectional survey that included adults ( $\geq 18$ years) who agreed to have their BP measured. Participants filled an anonymous, simple questionnaire including demographic and medical information. All participants provided oral informed consent. In addition, weight and height were measured if resources permitted; otherwise, these were estimated by screeners. The screening period lasted for $\sim 3$ weeks. We used a validated automatic oscillometric sphygmomanometer as a tool for $B P$ measurement. Three BP readings were taken in the sitting position, with 1-min interval between each reading, from the same arm either from the right or left. The average of the last two readings was used for analysing the results.
Participants were considered hypertensive if they had at least one of the following: systolic or diastolic BP $\geq 140$ and/or $\geq 90 \mathrm{mmHg}$, respectively, or taking antihypertensive medication. Data were collected using pre-prepared paper forms before sharing it online with the MMM project team for analysis. The mean of the $2 n d$ and 3 rd BP readings was estimated by multiple imputations using chained equations if either was missing as described elsewhere. ${ }^{7}$

## Results

The total number of participants over the 3 weeks was 7019 with $<4 \%$ having participated in the 2018 campaign. The mean age of the population was 46.0 ( $\mathrm{SD} \pm 16.6$ ) years. $57.5 \%$ of participants were male. Prevalence of smoking was high, at $51 \%$. In total, 1602 ( $22.8 \%$ ) participants reported taking antihypertensive medication, 5185 (73.9\%) were not taking any, and 232 (3.3\%) had an unknown status. $13.7 \%$ of the participants had never had their BP measured. Around $12.6 \%$ and $9.6 \%$ were using aspirin or a statin, respectively. The overall mean of the 2nd and 3rd BP measurements taken was $121.2 / 78.9 \mathrm{mmHg}$. Of all participants, 2572 (36.6\%) had hypertension. Among these, 64.1\% were aware of their disease, $62.3 \%$ were on one or more antihypertensive medications, and $39.0 \%$ had controlled BP (systolic BP $<140 \mathrm{mmHg}$ and diastolic BP $<90 \mathrm{mmHg}$ ) (Table 1). Out of 1602 participants on antihypertensive medication, $62.6 \%$ had controlled BP. Of all participants, 5417 were not taking antihypertensive medication or had an unknown status. Out of these participants, $17.9 \%$ had uncontrolled BP.

After adjusting for age, sex, and antihypertensive medication use, participants with diabetes mellitus (11.1\%) had a significantly higher systolic BP (by 2.34 mmHg ) as compared with participants without diabetes ( $P=0.002$ ). Moreover, body mass index was $26.7 \pm 4.7 \mathrm{~kg} / \mathrm{m}^{2}$ and correlated with BP readings. In fact, overweight (38.0\%) and obese participants (22.2\%) had a higher mean SBP/DBP of $3.6 / 2.0$ and $7.0 / 3.9 \mathrm{mmHg}$, respectively, as compared with participants with a healthy weight.

## Discussion

As part of the global MMM 2019 campaign, $36.6 \%$ of the 7019 Lebanese participants were found to be hypertensive, $64.1 \%$ of them were aware of it, and only $62.6 \%$ of treated participants had controlled BP.

Our results are in accordance with a recent study conducted in Beirut that included a representative sample of 501 participants, and reported a prevalence of hypertension of $36.4 \%$ with around $65.4 \%$ awareness of hypertension. ${ }^{5}$ Our results also suggest an apparent increase in prevalence of hypertension in Lebanon when compared with previous data, as prevalence of hypertension was $23 \%$ in $2005,31 \%$ in 2010, and up to $35.9 \%$ in 2015. ${ }^{4,6,8}$
In contrast to MMM 2018 global results, our population showed an increase in systolic BP in participants with diabetes. ${ }^{9}$ Notably, our results revealed a similar percentage of BP control and hypertension awareness, but they remain inadequate. These results emphasize the urgent need for efficient interventions to address these issues. Such interventions require the co-ordinated efforts of awareness campaigns, official health authorities, and health-care workers.

May Measurement Month has become a major yearly campaign aiming to raise awareness and screen for hypertension in Lebanon. In addition, it establishes a continuous annual tool for assessing these areas of concern. Compared with other screening campaigns, it is the largest campaign so far including participants older than 18 years from

Table 1 Total participants and proportions with hypertension, awareness, on medication and with controlled BP

| Total <br> participants | Percentage <br> with <br> hypertension | Percentage of <br> hypertensives <br> aware | Percentage of <br> hypertensives <br> on medication | Percentage of <br> those on medication | Percentage of <br> all hypertensives <br> with controlled <br> BP |
| :--- | :--- | :--- | :--- | :--- | :--- |
| 7019 | 36.6 | 64.1 | 62.3 | 62.6 | 39.0 |
| BP, blood pressure. |  |  |  |  |  |

various Lebanese cities. ${ }^{10}$ This cross-sectional screening study enrolled around $0.1 \%$ of the Lebanese population, but it is not considered to be a nationally representative sample as recruitment of participants was opportunistic and not randomized.

## Acknowledgements

We would like to thank all participants enrolled in the study as well as the volunteers, official authorities and all who contributed to the success of this campaign.

## Funding

## Servier Laboratories.

Conflict of interest: none declared.

## References

1. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J. Global disparities of hypertension prevalence and control. Circulation 2016; 134:441-450.
2. Zhou D, Xi B, Zhao M, Wang L, Veeranki SP. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study. Sci Rep 2018;8:9418.
3. Tailakh A, Evangelista LS, Mentes JC, Pike NA, Phillips LR, Morisky DE. Hypertension prevalence, awareness, and control in Arab countries: a systematic review. Nurs Health Sci 2014;16:126-130.
4. Tohme RA, Jurjus AR, Estephan A. The prevalence of hypertension and its association with other cardiovascular disease risk factors in a representative sample of the Lebanese population. J Hum Hypertens 2005;19:861-868.
5. Noubani A, Nasreddine L, Sibai AM, Tamim H, Isma'eel H. Prevalence, awareness, and control of hypertension in Greater Beirut Area, Lebanon. Int J Hypertens 2018;2018:1-15.
6. Matar D, Frangieh AH, Abouassi S, Bteich F, Saleh A, Salame E, Kassab R, Azar RR. Prevalence, awareness, treatment, and control of hypertension in Lebanon. J Clin Hypertens 2015; 17:381-388.
7. Beaney T, Schutte AE, Stergiou GS, Borghi C, Burger D, Charchar F, Cro S, Diaz A, Damasceno A, Espeche W, Jose AP, Khan N, Kokubo Y, Maheshwari A, Marin MJ, More A, Neupane D, Nilsson P, Patil M, Prabhakaran D, Ramirez A, Rodriguez P, Schlaich M, Steckelings UM, Tomaszewski M, Unger T, Wainford R, Wang J, Williams B, Poulter NR, on behalf of MMM Investigators. May Measurement Month 2019. Hypertension 2020;76:333-341
8. Mehio Sibai A, Nasreddine L, Mokdad AH, Adra N, Tabet M, Hwalla N. Nutrition transition and cardiovascular disease risk factors in Middle East and North Africa countries: reviewing the evidence. Ann Nutr Metab 2010;57:193-203.
9. Beaney T, Burrell LM, Castillo RR, Charchar FJ, Cro S, Damasceno A, Kruger R, Nilsson PM, Prabhakaran D, Ramirez AJ, Schlaich MP, Schutte AE, Tomaszewski M, Touyz R, Wang J-G, Weber MA, Poulter NR; the MMM Investigators. Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. Eur Heart J 2019;40: 2006-2017.
10. Yamout R, Adib SM, Hamadeh R, Freidi A, Ammar W. Screening for cardiovascular risk in asymptomatic users of the primary health care network in Lebanon, 2012-2013. Prev Chronic Dis 2014;11:E120.

[^0]:    *Corresponding author. Tel: +9613292629 , Fax: +9611577377 , Email: robertnajem@yahoo.fr

